Overview

Reduce Risk for Crohn's Disease Patients

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effectiveness of weekly subcutaneously administered Methotrexate for maintaining relapse-free sustained steroid/Enteral Nutrition -free 1-year remission compared with: - daily oral Azathioprine / 6 mercaptopurine in low risk paediatric Crohn's disease - subcutaneously administered adalimumab in high risk paediatric Crohn's disease
Phase:
Phase 4
Details
Lead Sponsor:
PIBD-Net
Collaborator:
European Commission
Treatments:
6-Mercaptopurine
Adalimumab
Azathioprine
Mercaptopurine
Methotrexate